Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myeloid leukemia

M W Deininger1, J M Goldman

  • 1Department of Haematology, Hammersmith Hospital, London, UK.

Current Opinion in Hematology
|September 25, 1998
PubMed
Summary
This summary is machine-generated.

New insights into BCR-ABL-positive leukemias reveal a p230BCR-ABL transcript linked to chronic neutrophilic leukemia. Research also explores ATM protein

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overexpression of EVI-1 in blast crisis of chronic myeloid leukemia.

Leukemia·1996
Same author

Organ-specific contribution to circulating C7 levels by the bone marrow and liver in humans.

European journal of immunology·1996
Same author

Phenotype and progeny of primitive adherent human hematopoietic progenitors.

Leukemia·1996
Same author

Expression of the LH2 gene in chronic myeloid leukaemia cells.

Leukemia·1996
Same author

Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results.

Leukemia·1996
Same author

Rarity of microsatellite alterations in acute myeloid leukaemia.

British journal of cancer·1996

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • BCR-ABL-positive leukemias, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), are driven by the BCR-ABL fusion gene.
  • Understanding the molecular mechanisms underlying these diseases is crucial for developing targeted therapies.
  • The ATM protein's role in DNA damage response and its potential interaction with ABL kinase activity warrants investigation.

Purpose of the Study:

  • To characterize novel BCR-ABL transcripts and their association with specific leukemia subtypes.
  • To investigate the role of ATM protein in regulating ABL kinase activity.
  • To explore the involvement of BCR-ABL in apoptosis inhibition through BCL-2 family proteins.
  • To identify therapeutic strategies for BCR-ABL-positive leukemias.

Related Experiment Videos

Main Methods:

  • Characterization of a novel p230BCR-ABL transcript.
  • Investigation of ATM protein's regulatory function in response to irradiation.
  • Analysis of signaling pathways linking BCR-ABL to the BCL-2 family.
  • Cloning of a 62-kD protein constitutively phosphorylated in CML progenitors.
  • Detection of Ph-negative long-term culture-initiating cells in CML patients.
  • Clinical trials evaluating treatment combinations (interferon alfa and cytarabine) and stem cell transplantation.

Main Results:

  • A new p230BCR-ABL transcript associated with Ph-positive chronic neutrophilic leukemia has been identified.
  • ATM protein is implicated as a regulator of ABL activity following irradiation.
  • Pathways involving BCR-ABL and BCL-2 proteins may contribute to apoptosis resistance in Ph-positive cells.
  • A 62-kD protein crucial in CML progenitors has been cloned.
  • Ph-negative long-term culture-initiating cells are present in many CML patients.
  • Interferon alfa combined with cytarabine shows superior efficacy compared to interferon alfa alone.
  • Autografting with in vivo-purged stem cells may lead to durable remissions.

Conclusions:

  • The characterization of p230BCR-ABL expands the understanding of BCR-ABL-related leukemias.
  • Targeting BCR-ABL tyrosine kinase with specific inhibitors represents a promising therapeutic avenue.
  • Combined therapies and stem cell transplantation offer potential for prolonged disease control.